- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.03. | Ernexa plant klinische Studie für Zelltherapie ERNA-101 bei Eierstockkrebs | 1 | Investing.com Deutsch | ||
| 31.03. | Ernexa plans ovarian cancer trial for cell therapy ERNA-101 | 1 | Investing.com | ||
| 31.03. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026 | 100 | GlobeNewswire (Europe) | Preclinical data demonstrate deep and durable tumor regressions with lead product candidate ERNA-101 in combination with PD-1 Blockade in ovarian cancer IND submission for ERNA-101 expected in Q3... ► Artikel lesen | |
| 20.03. | NASDAQ warnt Ernexa Therapeutics vor Delisting wegen niedrigem Aktienkurs | 4 | Investing.com Deutsch | ||
| 20.03. | Ernexa Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.03. | Ernexa Therapeutics Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| ERNEXA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 26.02. | Ernexa Therapeutics Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 20.02. | Ernexa Therapeutics Inc.: Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series | 1 | GlobeNewswire (USA) | ||
| 11.02. | Ernexa Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.02. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering | 189 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics Inc. (Nasdaq: ERNA) ("Ernexa" or the "Company"), an industry innovator developing novel cell therapies for the treatment of... ► Artikel lesen | |
| 05.02. | Ernexa Therapeutics Inc. - 8-A12B, Registration of securities | 1 | SEC Filings | ||
| 04.02. | Ernexa Therapeutics Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 03.02. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA | 1 | GlobeNewswire (USA) | ||
| 27.01. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program | 1 | GlobeNewswire (USA) | ||
| 06.01. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer | 1 | GlobeNewswire (USA) | ||
| 11.12.25 | Ernexa Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.12.25 | Ernexa Therapeutics: Aktie fällt trotz positiver Studiendaten | 2 | Investing.com Deutsch | ||
| 08.12.25 | Ernexa Therapeutics Inc.: Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer | 1 | GlobeNewswire (USA) | ||
| 03.12.25 | Ernexa Therapeutics Inc.: Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 02.12.25 | Ernexa Therapeutics appoints oncologist Dr. Winer to advisory board | 1 | Investing.com |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IMMUNOVANT | 26,550 | +5,65 % | Immunovant Inc.: Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 20,850 | +4,17 % | Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst | ||
| NURIX THERAPEUTICS | 16,300 | +2,45 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update | Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Enabling Phase 3 DAYBreak CLL-306 bexobrutideg... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 14,350 | +0,70 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones | Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommended... ► Artikel lesen | |
| TREVI THERAPEUTICS | 14,040 | +5,25 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates | Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 9,660 | -3,88 % | 4D Molecular Therapeutics, Inc.: 4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones | Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigators and patients; topline data... ► Artikel lesen | |
| ERASCA | 17,830 | +9,32 % | Jefferies reiterates Erasca stock Buy rating on rival trial data | ||
| ZENAS BIOPHARMA | 21,340 | +1,33 % | Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) | - Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare - - Obexelimab also met and demonstrated statistically... ► Artikel lesen | |
| TYRA BIOSCIENCES | 35,240 | -1,04 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| TANGO THERAPEUTICS | 24,070 | +11,75 % | Leerink raises Tango Therapeutics stock price target on PDAC data | ||
| ADMA BIOLOGICS | 10,490 | +1,16 % | ADMA Biologics, Inc.: ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research | Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and... ► Artikel lesen | |
| COGENT BIOSCIENCES | 36,480 | -0,05 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| MAZE THERAPEUTICS | 27,680 | +0,95 % | Zifo Technologies: Zifo and Maze Therapeutics Partner to Power Precision Medicine | SAN FRANCISCO, Feb. 18, 2026 /PRNewswire/ -- Zifo, the leading global enabler of AI and data-driven enterprise informatics for science driven organizations and Maze Therapeutics Inc have... ► Artikel lesen | |
| ARCELLX | 114,88 | +0,03 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 89,86 | +1,50 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma | KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track... ► Artikel lesen |
Das Unternehmen ERNEXA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,202 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ERNEXA THERAPEUTICS INC finden Sie auf Wallstreet Online.